전체 프로그램

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab Immunotherapy)

Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer · Non-Small Cell Lung Cancer

임상시험 1상태 DISCONTINUED

AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab Monotherapy)

Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase3#항체#면역항체+3

효능 ORR 16%임상시험 1상태 RECRUITING

AntibodystaleMerckPhase 1

pembrolizumab (Keytruda, Pembrolizumab Standard)

Metastatic Cancer · Metastatic Cancer

#MetastaticCancer#Antibody#Phase1#항체#면역항체+2

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab alone)

Colorectal Cancer · Colorectal Cancer

AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab and Chemotherapy drugs)

Non-small-cell Lung Cancer · Non-small-cell Lung Cancer

#Non-small-cellLungCancer#Antibody#Phase3#항체#면역항체+2

효능 ORR 62.1%임상시험 1상태 RECRUITING

AntibodystaleMerckPreclinical

pembrolizumab (Keytruda, Pembrolizumab combined Anlotinib)

High-Grade Serous Ovarian Cancer · High-Grade Serous Ovarian Cancer

#High-GradeSerousOvarianCancer#Antibody#Preclinical#항체#면역항체+2

#BreastCancer#Antibody#Phase2#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab infusion)

Breast Cancer · Breast Cancer

#Melanoma#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

효능 ORR 56.3%임상시험 1상태 ACTIVE

#RenalCellCarcinomaClearCell#Antibody#Phase2#항체#면역항체+5

pembrolizumab (Keytruda, Pembrolizumab plus denosumab)

Renal Cell Carcinoma, Clear Cell; Metastatic Kidney Cancer · Renal Cell Carcinoma, Clear Cell

#PD-1#Antibody#Phase2#항체#면역항체+4

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses)

HNSCC; Oral Cancer · PD-1

AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab, Sintilimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2

#EGFR#Antibody#Phase2#항체#면역항체+4

pembrolizumab (Keytruda, Pembrolizumab, pemetrexed, platinum)

Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor · EGFR

AntibodystaleDana-Farber Cancer InstitutePhase 2

Pembroluzimab (Pembroluzimab)

HPV-positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma · HPV-positive Oropharyngeal Squamous Cell

#HPV-positiveOropharyngealSquamou#Antibody#Phase2#항체#면역항체+3

효능 ORR 0.0%임상시험 1상태 RECRUITING

AntibodystaleXijing HospitalPreclinical

Penpulimab combination with anlotinib and chemotherapy (Penpulimab combination with anlotinib and chemotherapy)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Preclinical#항체#면역항체+2

AntibodystaleEli LillyPhase 1

Peri operative Cetuximab. (Peri operative Cetuximab.)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleRochePhase 3

trastuzumab (Herceptin, Perjeta plus trastuzumab, carboplatin and docetaxel)

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients · HER2

#HER2#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodystaleRochePhase 3

ZRC-3277 (Pertuzumab, Pertuzumab (ZRC-3277))

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase3#항체#면역항체+2

AntibodystaleRochePreclinical

neoadjuvant (Pertuzumab, Pertuzumab (neoadjuvant))

HER2-positive Breast Cancer; Neoplasms · HER2

#HER2#Antibody#Preclinical#항체#면역항체+4